U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07511647) titled 'A Phase 3 Clinical Study of QL2106 Injection' on March 30.
Brief Summary: It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya(R) in Patients with Moderate to Severe Plaque Psoriasis. A total of 318 subjects are planned to be included and randomized at a ratio of 1:1 to receive QL2106 injection orTremfya(R)
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Plaque Psoriasis
Intervention:
DRUG: QL2106 injection
Administer QL2106 injection by subcutaneous injection at Week 0, Week 4, and every 8 we...